Trials / Recruiting
RecruitingNCT07522099
Chinese Adults With Kidney Disease
A Phase 2 Study to Assess ADX-038 in Chinese Adults With Complement-Mediated Kidney Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- ADARx Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADX-038 | siRNA duplex oligonucleotide |
| DRUG | Telitacicept | fusion protein |
Timeline
- Start date
- 2026-07-23
- Primary completion
- 2028-07-10
- Completion
- 2029-01-21
- First posted
- 2026-04-13
- Last updated
- 2026-04-14
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07522099. Inclusion in this directory is not an endorsement.